|
MediciNova shares plunge as asthma drug fails in Ph IIb trial
The Pharma Letter MediciNova intends to design pivotal trial(s) that will include technological and operational improvements and further controls for medications that are not typically used in the treatment of acute exacerbations of asthma and were over-represented in … |
View full post on asthma – Google News